Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NKTR-118

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

naloxegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The role of naloxegol in the management of opioid-induced bowel dysfunction
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… Expand
  • figure 1
  • table 1
  • table 3
Is this relevant?
2015
2015
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
This randomized, double-blind, placebo-controlled, ascending-dose, crossover study evaluated single oral doses of naloxegol (NKTR… Expand
Is this relevant?
2015
2015
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Opioid-induced constipation (OIC) is the most common and often a treatment-limiting adverse event (AE) of opioid therapy for… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation
Naloxegol (previously known as NKTR-118) is a peripherally acting μ-opioid receptor antagonist engineered using polymer conjugate… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
New treatment possibilities for opioid-induced bowel dysfunction
The article by Webster et al. focused on the use of naloxegol in opioid-induced constipation (OIC) is important, as both OIC and… Expand
Is this relevant?
Review
2011
Review
2011
Opioid-Induced Constipation: Challenges and Therapeutic Opportunities
There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years… Expand
  • table 1
  • figure 1
Is this relevant?
2009
2009
NKTR-118 Significantly Reverses Opioid-Induced Constipation
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of… Expand
  • figure 1
Is this relevant?
2009
2009
Efficacy, Safety and Pharmacokinetics of Oral NKTR-118 in Patients with Opioid-Induced Constipation: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 Study: 466
 
Is this relevant?
2009
2009
AstraZeneca Inks Deal with Nektar
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR… Expand
Is this relevant?
2008
2008
(210) Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE